Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Buchanan

Showing results (271-280 of 303) with videos related to

Pageof 31
Sort By:
Molecular Cancer Therapeutics|February 6, 2016
ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR EpitopeAndrew C Phillips, Erwin R Boghaert, Kedar S Vaidya, et al.
Plos One|July 7, 2015
The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of LeukemiaWilliam N Pappano, Jun Guo, Yupeng He, et al.
American Journal of Hospital Pharmacy|December 1, 1976
Computerized consultation system for selection of antimicrobial therapyS M Wraith, J S Aikins, B G Buchanan, et al.
Oncogene|October 24, 2017
RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1S-H Chen, X Gong, Y Zhang, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Pyrimidine-based tricyclic molecules as potent and orally efficacious inhibitors of wee1 kinaseYunsong Tong, Maricel Torrent, Alan S Florjancic, et al.
Oncotarget|May 12, 2020
Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cellsLacey M Litchfield, Karsten Boehnke, Manisha Brahmachary, et al.
BMC Cancer|September 8, 2009
Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605William N Pappano, Paul M Jung, Jonathan A Meulbroek, et al.
Nature Cancer|September 27, 2021
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degradersXuewei Wu, Xiaobao Yang, Yan Xiong, et al.
Molecular Cancer Therapeutics|March 4, 2015
Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal AntibodyEdward B Reilly, Andrew C Phillips, Fritz G Buchanan, et al.
Cancer Research|March 10, 2021
Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid TumorsDarren C Phillips, Fritz G Buchanan, Dong Cheng, et al.
Pageof 31

Showing results (271-280 of 303) with videos related to

Sort By:
Pageof 31
Molecular Cancer Therapeutics|February 6, 2016
ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR EpitopeAndrew C Phillips, Erwin R Boghaert, Kedar S Vaidya, et al.
Plos One|July 7, 2015
The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of LeukemiaWilliam N Pappano, Jun Guo, Yupeng He, et al.
American Journal of Hospital Pharmacy|December 1, 1976
Computerized consultation system for selection of antimicrobial therapyS M Wraith, J S Aikins, B G Buchanan, et al.
Oncogene|October 24, 2017
RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1S-H Chen, X Gong, Y Zhang, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Pyrimidine-based tricyclic molecules as potent and orally efficacious inhibitors of wee1 kinaseYunsong Tong, Maricel Torrent, Alan S Florjancic, et al.
Oncotarget|May 12, 2020
Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cellsLacey M Litchfield, Karsten Boehnke, Manisha Brahmachary, et al.
BMC Cancer|September 8, 2009
Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605William N Pappano, Paul M Jung, Jonathan A Meulbroek, et al.
Nature Cancer|September 27, 2021
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degradersXuewei Wu, Xiaobao Yang, Yan Xiong, et al.
Molecular Cancer Therapeutics|March 4, 2015
Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal AntibodyEdward B Reilly, Andrew C Phillips, Fritz G Buchanan, et al.
Cancer Research|March 10, 2021
Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid TumorsDarren C Phillips, Fritz G Buchanan, Dong Cheng, et al.
Pageof 31